Develops and commercializes novel solutions for specialty cancers and urothelial diseases. Utilizes a proprietary RTGel technology for improved drug delivery. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 23% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 16% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 23% a year on average.
Sales run at $109.8M a year. A small number, but proof the product has real buyers.
A loss of $153.5M against $109.8M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, URGN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: URGN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (53/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.